Galapagos Urged To Get The Cheque Book Out For Bigger BD

Galapagos NV CEO Paul Stoffels believes the company has been transformed into "a pure-play biotech with a revitalized pipeline" after a turbulent few years but some observers are wondering when the Belgian firm will dip into its very considerable cash pile for a transformational deal.

There have been a number of strategic shifts at Galapagos, which has been hit by a number of high-profile clinical failures and setbacks for its JAK inhibitor Jyseleca (filgotinib) that was once touted as a blockbuster but is now in the hands of Italy's Alfasigma SpA. Since then, Stoffels claimed that "we've put in place strong leadership with a track record of delivering transformative drugs [and are] taking a collaborative approach combining internal and external innovation